Accropeutics Secures $12M Series B to Propel Valo Therapeutics’ Next-Gen Immunotherapy Breakthroughs

Valo Therapeutics (ValoTx), a pioneering developer of novel immunotherapies in cancer and infectious disease, today announced a significant funding milestone, raising $12,000,000 from Accropeutics.

This investment underscores the firm’s innovative approach, which leverages oncolytic viruses and viral vectors in combination with disease-specific peptides to create highly adaptable and immunogenic therapeutic vaccination platforms.

As a dynamic spin-out from the University of Helsinki, Finland, ValoTx has rapidly evolved into a leader in the immunotherapy space by assembling a diverse team of world-class immunotherapy experts along with founding scientists whose deep-rooted experience is crucial for driving their patented technology through clinical development.

The robust backing from Accropeutics not only validates the company’s vision but also accelerates its mission to transform laboratory innovations into viable, patient-accessible treatments.

The funding will be strategically deployed to further advance clinical trials, fine-tune the therapeutic platforms, and expand the pipeline for both cancer and infectious disease programs.

This injection of capital marks a critical business milestone, reflecting confidence in the management team’s proven track record of successfully steering companies from inception to full stock exchange listings.

As ValoTx grows its clinical and commercial footprint, the new funds will also support the scaling-up of manufacturing capabilities and fortification of regulatory infrastructures across multiple markets.

By merging scientific ingenuity with robust clinical execution, Valo Therapeutics is now even better positioned to deliver transformative therapies to patients in need, potentially reshaping the treatment landscape for some of the most challenging and life-threatening conditions of our time.